| |
For researchers unaffiliated with an academic library, finding scientific papers can be time-consuming and expensive—and organizing or sharing them can be even harder. Can a new tool address this gap? Learn more. 
|
|
Today's Big NewsDec 9, 2022 |
| By Annalee Armstrong Gilead landed its Kite unit at Arcellx to work on a phase 2 multiple myeloma cell therapy, a deal worth $225 million upfront plus a $100 million equity investment. |
|
|
|
By Annalee Armstrong Regeneron’s George Yancopoulos drew boos from the crowd at a conference in Washington, D.C., as he touted innovation in pharma above cost considerations for expensive treatments. |
By Nick Paul Taylor AstraZeneca’s $1 billion bet on Daiichi Sankyo’s TROP2 antibody-drug conjugate delivered promising early-phase breast cancer data. Chasing Gilead, the partners have linked the TROP2-directed ADC datopotamab deruxtecan to response and survival results that suggest they have a shot at coming from behind to disrupt the market. |
By Nick Paul Taylor Autolus Therapeutics is almost ready to make a late play for the CD19 CAR-T cell therapy space. The biotech now has phase 2 data showing its asset hit the primary endpoint at an interim analysis and is setting out plans for further data to file for FDA approval next year and try to join Bristol Myers Squibb, Gilead and Novartis on the market. |
|
Learn about this important section, the studies that are expected and how to develop the section over time… Read More >> 
|
|
By Annalee Armstrong Novartis’ naporafenib is ready for phase 2, but it won’t be heading there with the Swiss Pharma in the driver’s seat. Instead, Erasca has signed a $20 million licensing deal to take the melanoma therapy into mid-stage development. |
By Helen Floersh Scientists have found a direct link between misfolded proteins caused by gene therapy in liver cells and liver cancer development in mice fed a high-fat diet. |
By Teresa Carey This week on “The Top Line,” we discuss the latest from the Clinical Trials on Alzheimer’s Disease conference. Plus, we cover the week's news including an investigation into Neuralink, Google’s DeepMind and why things aren't working out for PI3Ks. |
By Gabrielle Masson,Andrea Park Roche Diagnostics tapped Brad Moore to lead the testmaker’s North American division as CEO. |
By Zoey Becker After meeting with the FDA last month, MEI and Kyowa Kirin halted development of their B-cell malignancy prospect outside of Japan. Takeda’s dengue fever vaccine nabbed a crucial nod in Europe. Plus more. |
By Ben Adams You have to double-check that a recent tweet out from Pfizer’s official corporate account was in fact real and not from the slew of imposter accounts set up in recent weeks designed to tweet controversial statements under the guise of an official account. |
By Heather Landi Deal valuations in 2022 were largely driven by activity in the home health and hospice markets, such as CVS’ acquisition of Signify Health for $8 billion and UnitedHealth's $6 billion deal to buy LHC Group. This sector will continue to be a robust area for investment in 2023, PwC's Nick Donkar said. |
By Andrea Park After serving as Edwards Lifesciences’ chairman and chief executive since its 2000 spinout from Baxter International, Michael Mussallem is stepping down. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we discuss the latest from the Clinical Trials on Alzheimer’s Disease conference. Plus, we cover the week's news including an investigation into Neuralink, Google’s DeepMind and why things aren't working out for PI3Ks. |
|
|---|
|
|
|
Thursday, December 15, 2022 | 11am ET / 8am PT Cell therapy products have amazing potential to treat a wide variety of diseases and vast numbers of patients globally. In this webinar we discuss what these key challenges are, how to approach these challenges and some opportunities available to better the process. Register now. 
|
|
Video Revolutionize your monoclonal antibody (mAb) manufacturing with expert insights. Sponsored by: Gibco |
Whitepaper Learn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
